Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. It is manufactured and marketed under the brand name Strattera^® by Eli Lilly and Company. There is currently no generic available within the United States due to patent restrictions; however, a generic is available outside the United States, which is manufactured by Torrent Pharmaceuticals.

Atomoxetine is classified as a norepinephrine reuptake inhibitor, and is approved for use in children, adolescents, and adults. However, its efficacy has not been studied in children under 6 years old. Its advantage over stimulants for the treatment of ADHD is that it has less abuse potential than stimulants, is not scheduled as a controlled substance and has proven in clinical trials to offer 24 hour coverage of symptoms associated with ADHD in adults and children.

More on [ Atomoxetine ]

Atomoxetine - Twitter Search

Targeted Pharmacological Interventions for Autism: A DoubleBlind, PlaceboControlled Study of Atomoxetine in Childr... http://ow.ly/16bVSg
pickylist (Indy's PickyList.com) Mon, 21 Dec 2009 16:41:15 -0000
Targeted Pharmacological Interventions for Autism: A DoubleBlind, PlaceboControlled Study of Atomoxetine in Childr... http://ow.ly/16bVSg
safety assessment of atomoxetine w/ ma iv administration http://bit.ly/5YhPTT
_clinical_trial (Clinical Trials) Sun, 20 Dec 2009 11:18:43 -0000
safety assessment of atomoxetine w/ ma iv administration http://bit.ly/5YhPTT
safety assessment of atomoxetine w/ ma iv administration http://bit.ly/5YhPTT
ustrials (US Trials) Sun, 20 Dec Subscribe to Atomoxetine RSS feed